The China Mail - Treatment improves cognition in Down Syndrome patients

USD -
AED 3.672503
AFN 63.999525
ALL 81.442168
AMD 361.356205
ANG 1.789785
AOA 918.000161
ARS 1533.897396
AUD 1.423893
AWG 1.8025
AZN 1.698106
BAM 1.751936
BBD 2.019841
BDT 124.502291
BGN 1.747831
BHD 0.378636
BIF 3009.562199
BMD 1
BND 1.2812
BOB 12.160165
BRL 5.436496
BSD 1.002889
BTN 95.171425
BWP 13.855559
BYN 2.954181
BYR 19600
BZD 2.016885
CAD 1.39828
CDF 2314.999657
CHF 0.824645
CLF 0.025235
CLP 993.180505
CNY 6.661103
CNH 6.65047
COP 3218.67
CRC 456.02956
CUC 1
CUP 24.068509
CVE 98.772786
CZK 21.819698
DJF 178.577987
DKK 6.692302
DOP 60.786026
DZD 135.75098
EGP 55.948402
ERN 15
ETB 161.902139
EUR 0.89545
FJD 2.243694
FKP 0.746765
GBP 0.747145
GEL 2.601308
GGP 0.746765
GHS 11.683612
GIP 0.746765
GMD 74.000289
GNF 8876.049714
GTQ 7.66695
GYD 210.211851
HKD 7.845625
HNL 26.9551
HRK 6.76901
HTG 131.391307
HUF 327.662999
IDR 18178
ILS 3.14456
IMP 0.746765
INR 94.89915
IQD 1520.31173
IRR 1868415.000146
ISK 121.770252
JEP 0.746765
JMD 159.364013
JOD 0.708976
JPY 157.902998
KES 129.860389
KGS 87.4487
KHR 4091.870006
KMF 441.000151
KPW 899.999961
KRW 1344.329837
KWD 0.31117
KYD 0.835759
KZT 454.722981
LAK 22579.734941
LBP 89806.69145
LKR 333.576685
LRD 170.480349
LSL 16.713128
LTL 2.95274
LVL 0.60489
LYD 6.446758
MAD 9.860886
MDL 17.951359
MGA 4536.110178
MKD 55.157433
MMK 2099.693878
MNT 3599.326016
MOP 8.10391
MRU 40.665547
MUR 47.289846
MVR 15.450609
MWK 1738.573508
MXN 18.784603
MYR 4.067095
MZN 63.909964
NAD 16.713053
NGN 1344.520182
NIO 36.905162
NOK 9.213697
NPR 152.274101
NZD 1.78191
OMR 0.384271
PAB 1.003001
PEN 3.471087
PGK 4.563879
PHP 63.645496
PKR 277.436793
PLN 3.95285
PYG 5875.265928
QAR 3.655843
RON 4.7806
RSD 105.271644
RUB 80.749652
RWF 1480.416527
SAR 3.764539
SBD 8.058206
SCR 14.712529
SDG 601.496843
SEK 9.816305
SGD 1.27969
SHP 0.748335
SLE 22.897509
SLL 20969.504398
SOS 573.104915
SRD 37.619501
STD 20697.981008
STN 21.946031
SVC 8.775026
SYP 13001.999685
SZL 16.707648
THB 33.772503
TJS 9.231424
TMT 3.5
TND 2.999059
TOP 2.40776
TRY 49.967796
TTD 6.799808
TWD 32.679037
TZS 2643.750271
UAH 45.485612
UGX 4262.104179
UYU 40.318896
UZS 12028.32407
VES 887.479799
VND 25786.5
VUV 118.915185
WST 2.776217
XAF 587.376773
XAG 0.019993
XAU 0.000256065553
XCD 2.70255
XCG 1.807408
XDR 0.707052
XOF 587.376773
XPF 106.82886
YER 236.202996
ZAR 16.713802
ZMK 9001.200364
ZMW 20.222595
ZWL 321.999592
SSP 5745.217636
MXV 2.117127
  • RYCEF

    0.4000

    19.71

    +2.03%

  • CMSC

    0.0000

    20.4

    0%

  • BTI

    0.4200

    56.05

    +0.75%

  • BP

    0.2800

    44.43

    +0.63%

  • RBGPF

    1.6000

    67

    +2.39%

  • RIO

    -0.1500

    94.41

    -0.16%

  • AZN

    -0.4300

    166.15

    -0.26%

  • GSK

    0.4600

    49.7

    +0.93%

  • BCE

    -0.4100

    20.56

    -1.99%

  • NGG

    -0.2500

    75.24

    -0.33%

  • VOD

    -0.0400

    16.58

    -0.24%

  • RELX

    -0.4500

    33.07

    -1.36%

  • BCC

    -0.5500

    76.59

    -0.72%

  • CMSD

    -0.0300

    20.27

    -0.15%

  • JRI

    -0.2500

    10.77

    -2.32%

Treatment improves cognition in Down Syndrome patients
Treatment improves cognition in Down Syndrome patients / Photo: © AFP/File

Treatment improves cognition in Down Syndrome patients

A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.

Text size:

However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.

"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.

Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.

Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.

Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.

GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.

"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.

- Mice research -

The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.

They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.

The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.

A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.

They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.

Cognition and smell tests were carried out during the treatment, as were MRI scans.

Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.

"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.

The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.

- 'Improve quality of life' -

The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".

"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.

A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.

"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.

Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".

He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.

It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.

"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."

X.So--ThChM